Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (624)	2/14/2007 5:04:10 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

And Adam Feu continues his tirade of INGN.<g> He states that that INGN's retrospectively finding significant correlation of abnormal p53 protein levels with increased survival of patients treated with ADVEXIN p53 therapy is similar to retrospectively finding that left handed patients had a better outcome than right handed patients. Apparently he thinks that ADVEXIN has some left handed gene or that it had been previously found some association between lung cancer and left handed patients.<g> thestreet.com His comments about the fact that because the abnormal p53 was not the primary goal of ADVEXIN's trial, the finding that the median survival of patients with tumors abnormally expressing p53 was 11.6Ms vs. only 3.5 months in patients whose tumors did not have the p53 biomarker should be ignored. According to him,PFE should have ignored sildenafil citrate because it wasn't as effective as expected for its primary goal which was treating hypertension. With INGN's good size short position & the fact that in his tirade he makes no mention of INGN 241,INGN 225,INGN 401, INGN 234,INGN 402,INGN 403 or INGN 007 one has to question the ultimate reason for his one sided tirade.<g> Bernard